Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension. Omidenepag was approved for medical use in Japan in 2018, and in the United States in September 2022.
Medical uses Omidenepag is indicated for the treatment of glaucoma and ocular hypertension.
Adverse effects The most common adverse effects of omidenepag are conjunctival hyperemia and macular edema, including cystoid macular edema.
Pharmacology Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag. Omidenepag is a selective prostaglandin E2 receptor agonist.
History Omidenepag was developed by Ube Industries and Santen Pharmaceutical.
References
External links "Omidenepag". NCI Thesaurus. "Omidenepag isopropyl". NCI Thesaurus.